Streetbeat News

Analyst Ratings

PSA

Stifel analyst Steve Manaker maintains a 'Buy' rating on Public Storage (NYSE:PSA) but lowers the price target from $360 to $330.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 2:29 pm

IOVA

Stifel analyst Benjamin Burnett has maintained a 'Buy' rating on Iovance Biotherapeutics (NASDAQ:IOVA) but lowered the price target from $27 to $25.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 2:28 pm

CRM

Truist Securities analyst Terry Tillman has reiterated a 'Buy' rating on Salesforce (NYSE:CRM) and maintained a price target of $275.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 2:26 pm

GEO

Citron Research has tweeted about Geo Group's stock, potentially influencing its performance.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 2:25 pm

PFE

Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Pfizer (NYSE:PFE) and maintained a price target of $62.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 2:24 pm

RCKT

Rocket Pharmaceuticals announced alignment with the FDA on the global Phase 2 pivotal trial of RP-A501 for Danon Disease. The trial will evaluate the efficacy and safety of RP-A501 in 12 patients. William Blair analysts see the update positively and believe it de-risks the pivotal trial. Rocket Pharmaceuticals also announced an equity offering of $175 million. RCKT shares are up 39.70%.

Portfolio Pulse from Vandana Singh

September 13, 2023 | 2:23 pm

AAPL

AMZN

META

MSFT

NVDA

QQQ

SPY

TSLA

Market Clubhouse's Morning Memo discusses trade strategies for SPY, QQQ, AAPL, MSFT, META, AMZN, TSLA, and NVDA. The analysis is based on a proprietary formula that considers price, volume, and options flow. The memo provides potential price levels for each asset and advises traders to monitor these stocks closely and be prepared to leverage potential breakouts or reversals.

Portfolio Pulse from RIPS

September 13, 2023 | 2:22 pm

PRCT

Truist Securities analyst Richard Newitter has reiterated a 'Buy' rating on PROCEPT BioRobotics (NASDAQ:PRCT) and maintained a price target of $49.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 2:22 pm

EXEL

Truist Securities analyst Asthika Goonewardene has reiterated a 'Buy' rating on Exelixis (NASDAQ:EXEL) and maintained a price target of $32.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 2:21 pm

ZION

Truist Securities analyst Jennifer Demba has reiterated a 'Buy' rating on Zions Bancorp (NASDAQ:ZION) and maintained a price target of $42.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2023 | 2:21 pm